佳息患联合施多宁治疗艾滋病病毒1型感染的免疫反应效果

目的　 观察非核苷类逆转录酶抑制剂施多宁与蛋白酶抑制剂佳息患联合用于治疗艾滋病病毒 1型 (HIV 1 )后的机体免疫反应。 方法　2 0例HIV 1慢性感染者 ,在治疗前后定期采集外周血 ,分离血浆及单个核细胞 ,检测病毒载量及T淋巴细胞亚群。 结果　治疗后 ,病人血浆中HIV 1核糖核酸 (RNA)含量降低 ,CD+ 4T淋巴细胞数量增多 ,其免疫系统活化指标趋向于正常。 结论　施多宁与佳息患联合治疗有效地抑制了HIV 1的复制 ,并提示机体免疫功能得以部分改善

Virological and Immunological Outcomes in HIV-1-Infected Chinese Patients Treated with A Combination of Efavirenz and Indinavir for 48 Weeks

Objective After completing the first therapeutic trial utilizing Combivir plus Indinavir in HIV-1-infected patients in China two years ago,we initiated a second clinical trial using a combination of Efavirenz and Indinavir,and observed its virological and immunological outcomes. Methods Twenty patients with chronic HIV-1 infection were recruited. Blood samples were collected at the baseline and different times after the initiation of HAART treatment. Within 48hr after obtaining blood samples,plasma and peripheral blood mononuclear cells were separated and cyropreserved by routine methods. HIV-1 viral load was measured using plasma samples,CD + 4 and CD + 8T cell subsets were determined using flow cytometry. Result The drug regimen was effective in reducing HIV-1 plasma viral load and increasing total CD + 4T cell counts. The levels of CD38 and HLA-DR expression on T cells tended to normalize shortly after the initiation of HAART treatment. Conclusions The combination of Efavirenz and Indinavir was generally well tolerated and effective in reducing HIV-1 RNA. It also improved immunological functions.